CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

11 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

10 7 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

01 6 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 5 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

09 5 2023 15:30:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

02 5 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

27 4 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

19 4 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

18 4 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

12 4 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

05 4 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

09 3 2023 15:05:01 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

23 2 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

21 2 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

07 2 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Leadership Team Update

06 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

02 2 2023 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

22 11 2022 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

10 11 2022 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

09 11 2022 06:15:00 提供 Nasdaq GlobeNewswire